A BILL 
To amend the Public Health Service Act to establish an 
Emergency Office of Manufacturing for Public Health, 
and for other purposes. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. SHORT TITLE. 
3
This Act may be cited as the ‘‘Pandemic Emergency 
4
Manufacturing Act of 2021’’. 
5
SEC. 2. PUBLIC MANUFACTURING OF PHARMACEUTICALS. 
6
Part A of title III of the Public Health Service Act 
7
(42 U.S.C. 241 et seq.) is amended by adding at the end 
8
the following: 
9
22:57 Feb 21, 2021
H728
2 
•HR 728 IH
‘‘SEC. 310B. MANUFACTURING OF DRUGS, BIOLOGICAL 
1
PRODUCTS, DEVICES, AND PERSONAL PRO-
2
TECTIVE EQUIPMENT. 
3
‘‘(a) EMERGENCY OFFICE OF MANUFACTURING FOR 
4
PUBLIC HEALTH.— 
5
‘‘(1) ESTABLISHMENT.—There is established 
6
within the Department of Health and Human Serv-
7
ices an office to be known as the Emergency Office 
8
of Manufacturing for Public Health (referred to in 
9
this section as the ‘Office’). 
10
‘‘(2) PURPOSE.—The purposes of the Office 
11
are— 
12
‘‘(A) to ensure an adequate supply of, and 
13
increase access to, prescription drugs, biological 
14
products, devices, and other supplies, including 
15
personal protective equipment, necessary to, as 
16
appropriate, diagnose, mitigate, prevent, or 
17
treat COVID–19 and to mitigate the harm the 
18
COVID–19 pandemic might otherwise cause for 
19
the strategic national stockpile under section 
20
319F–2, Federal, State, local, and Native 
21
health programs, and the commercial market; 
22
‘‘(B) to address shortages in the strategic 
23
national stockpile and commercial market of 
24
prescription drugs, biological products, devices, 
25
22:57 Feb 21, 2021
H728
3 
•HR 728 IH
and personal protective equipment used to treat 
1
conditions other than COVID–19; and 
2
‘‘(C) to provide prescription drugs, biologi-
3
cal products, devices, and personal protective 
4
equipment necessary to diagnose, mitigate, pre-
5
vent, and treat COVID–19 and to mitigate the 
6
harm the COVID–19 pandemic might otherwise 
7
cause, to Federal, State, local, and Native 
8
health programs, at no cost, and to consumers 
9
in the commercial market and other inter-
10
national entities at cost. 
11
‘‘(3) PERSONNEL.— 
12
‘‘(A) DIRECTOR.— 
13
‘‘(i) IN GENERAL.—The Office shall 
14
be headed by a Director, who shall be ap-
15
pointed by the President, not later than 15 
16
days after the date of enactment of the 
17
Pandemic Emergency Manufacturing Act 
18
of 2021, by and with the advice and con-
19
sent of the Senate. 
20
‘‘(ii) ACTING DIRECTOR.—The Assist-
21
ant Secretary for Preparedness and Re-
22
sponse, if in compliance with subparagraph 
23
(C), may serve as Director of the Office in 
24
an acting capacity until the later of Senate 
25
22:57 Feb 21, 2021
H728
4 
•HR 728 IH
confirmation of a Director or 3 months 
1
after date of enactment of the Pandemic 
2
Emergency Manufacturing Act of 2021. 
3
‘‘(iii) COMPENSATION.—The Director 
4
shall be compensated at the rate prescribed 
5
for level III of the Executive Schedule 
6
under section 5314 of title 5, United 
7
States Code. 
8
‘‘(B) EMPLOYEES.—The Director of the 
9
Office, in consultation with the Secretary, may 
10
fix the number of, and appoint and direct, all 
11
employees of the Office. 
12
‘‘(C) BANNED INDIVIDUALS.— 
13
‘‘(i) DRUG COMPANY LOBBYISTS.—No 
14
former registered drug manufacturer lob-
15
byist— 
16
‘‘(I) may be appointed to the po-
17
sition of Director of the Office; or 
18
‘‘(II) may be employed by the Of-
19
fice during the 6-year period begin-
20
ning on the date on which the reg-
21
istered lobbyist terminates its reg-
22
istration in accordance with section 
23
4(d) of the Lobbying Disclosure Act 
24
22:57 Feb 21, 2021
H728
5 
•HR 728 IH
of 1995 or the agent terminates its 
1
status, as applicable. 
2
‘‘(ii) SENIOR
EXECUTIVES
OF
LAW- 
3
BREAKING COMPANIES.—No former senior 
4
executive of a covered entity— 
5
‘‘(I) may be appointed to the po-
6
sition of Director of the Office; or 
7
‘‘(II) may be employed by the Of-
8
fice during the 6-year period begin-
9
ning on the later of— 
10
‘‘(aa) the date of the settle-
11
ment; and 
12
‘‘(bb) the date on which the 
13
enforcement 
action 
has 
con-
14
cluded. 
15
‘‘(iii) COVERED
ENTITY.—For pur-
16
poses of clause (ii), the term ‘covered enti-
17
ty’ means any entity that is— 
18
‘‘(I) a drug manufacturer; and 
19
‘‘(II)(aa) operating under Fed-
20
eral settlement, including a Federal 
21
consent decree; or 
22
‘‘(bb) the subject of an enforce-
23
ment action in a court of the United 
24
States or by an agency. 
25
22:57 Feb 21, 2021
H728
6 
•HR 728 IH
‘‘(4) DUTIES.— 
1
‘‘(A) IN GENERAL.—The Office shall— 
2
‘‘(i) prepare and submit applications 
3
for approval to the Food and Drug Admin-
4
istration, or enter into contracts for such 
5
submission, for the manufacture of appli-
6
cable COVID–19 products and other appli-
7
cable drugs, biological products, and de-
8
vices when authorized under this section; 
9
‘‘(ii) obtain rights to manufacture ap-
10
plicable COVID–19 products and applica-
11
ble drugs, biological products, and devices 
12
as authorized under this section; 
13
‘‘(iii) manufacture, or enter into con-
14
tracts with entities to manufacture, appli-
15
cable COVID–19 products and other appli-
16
cable drugs, biological products, and de-
17
vices as authorized under this section; 
18
‘‘(iv) determine a fair price for each 
19
applicable drug, biological product, and de-
20
vice, in accordance with subparagraph 
21
(B)(ii); 
22
‘‘(v) 
sell 
manufactured 
applicable 
23
drugs, biological products, and devices at a 
24
fair price, as authorized under this section; 
25
22:57 Feb 21, 2021
H728
7 
•HR 728 IH
‘‘(vi) provide, at no cost, applicable 
1
COVID–19 products to Federal, State, 
2
local, and Native health programs, and 
3
other domestic health care providers and 
4
suppliers, as determined by the Secretary; 
5
‘‘(vii) sell, at-cost, applicable COVID– 
6
19 products to other commercial entities 
7
and international entities, in accordance 
8
with subparagraph (B)(i); and 
9
‘‘(viii) manufacture, or enter into con-
10
tracts with entities to manufacture, active 
11
pharmaceutical ingredients for use by the 
12
Office or for sale to other entities. 
13
‘‘(B) PRICING DETERMINATIONS.— 
14
‘‘(i) AT-COST PRICE.—In determining 
15
an at-cost price for an applicable COVID– 
16
19 product under subparagraph (A)(vii) 
17
the Office shall consider— 
18
‘‘(I) the cost to the Federal Gov-
19
ernment of manufacturing the appli-
20
cable COVID–19 product; 
21
‘‘(II) the administrative costs of 
22
operating the Office; and 
23
22:57 Feb 21, 2021
H728
8 
•HR 728 IH
‘‘(III) the cost to acquire or man-
1
ufacture applicable COVID–19 prod-
2
uct under this section. 
3
‘‘(ii) FAIR PRICE.—In determining a 
4
fair price for an applicable drug, biological 
5
product, or device under subparagraph 
6
(A)(iv) the Office shall consider— 
7
‘‘(I) the impact of price on pa-
8
tient access to the applicable drug, bi-
9
ological product, or device; 
10
‘‘(II) the cost of the applicable 
11
drug, biological product, or device to 
12
Federal or State health care pro-
13
grams; 
14
‘‘(III) the cost to the Federal 
15
Government of manufacturing the ap-
16
plicable drug, biological product, or 
17
device; 
18
‘‘(IV) the administrative costs of 
19
operating the Office; 
20
‘‘(V) the cost to acquire or manu-
21
facture the applicable drug, biological 
22
product, or device under this section; 
23
and 
24
22:57 Feb 21, 2021
H728
9 
•HR 728 IH
‘‘(VI) the impact of price on 
1
market competition for the applicable 
2
drug, biological product, or device. 
3
‘‘(iii) 
TRANSPARENCY.—All 
prices 
4
charged for applicable COVID–19 products 
5
and applicable drugs, biological products, 
6
or devices shall be made publicly available 
7
by the Office. 
8
‘‘(C) OBTAINING
RIGHTS
TO
MANUFAC-
9
TURE AND MARKET.— 
10
‘‘(i) IN GENERAL.—When necessary to 
11
fulfill the Office’s duties under this section, 
12
the Office shall acquire the rights to manu-
13
facture and market applicable COVID–19 
14
products and applicable drugs, biological 
15
products, and devices as authorized under 
16
this section. 
17
‘‘(ii) LICENSING AUTHORITY.— 
18
‘‘(I) 
IN
GENERAL.—Notwith-
19
standing any other provision of law, 
20
the Secretary shall issue licenses, as 
21
useful for fulfilling the duties under 
22
this Act, allowing the Office to prac-
23
tice or have practiced (which may in-
24
clude licensure of retroactive practice) 
25
22:57 Feb 21, 2021
H728
10 
•HR 728 IH
any invention in the United States or 
1
territories of the United States, in-
2
cluding making, using, offering to sell 
3
or selling, importing, or exporting 
4
such invention, to reference or rely 
5
upon clinical trial data submitted to a 
6
regulatory authority or the grant of 
7
marketing approval, and to access and 
8
use otherwise confidential informa-
9
tion, including know-how, related to 
10
the manufacture of an applicable 
11
COVID–19 
product 
or 
applicable 
12
drug, biological product, or device. 
13
‘‘(II) NON-VOLUNTARY
LICENS-
14
ING.—For any license that involves a 
15
non-voluntary authorization to use 
16
patented inventions, regulatory test 
17
data, data, know-how or other intel-
18
lectual property rights, the license 
19
shall provide for reasonable remunera-
20
tion to rights holders such as a rea-
21
sonable royalty on the sales of prod-
22
uct, a 1-time payment, or some com-
23
bination, provided that the combined 
24
royalty payments to all rights holders 
25
22:57 Feb 21, 2021
H728
11 
•HR 728 IH
shall not exceed the percentage of 
1
sales that is the average percent of all 
2
royalty payments reported to the In-
3
ternal Revenue Service by companies 
4
in the pharmaceutical and medicines 
5
sector, North American Industry Clas-
6
sification System code 325410, pro-
7
vided that when products are distrib-
8
uted for free, the royalty shall be 
9
based upon the cost of goods. When 
10
there are multiple rights holders, the 
11
allocation of the total royalty pay-
12
ments shall be determined by— 
13
‘‘(aa) agreement among the 
14
rights holders; 
15
‘‘(bb) allocation by arbitra-
16
tion among the rights holders; or 
17
‘‘(cc) if neither item (aa) 
18
nor (bb) applies, by the Office. 
19
‘‘(iii) 
TRANSPARENCY.—Subject 
to 
20
clause (iv), the Secretary shall post any 
21
contract agreement under subparagraph 
22
(A) or license issued under clause (ii) on 
23
the public internet website of the Depart-
24
ment of Health and Human Services, on 
25
22:57 Feb 21, 2021
H728
12 
•HR 728 IH
the date on which such agreement or li-
1
cense takes effect. 
2
‘‘(iv) PROTECTED INFORMATION.—In 
3
carrying out this section, the Secretary 
4
shall enforce applicable law concerning the 
5
protection of confidential commercial infor-
6
mation and trade secrets. 
7
‘‘(D) ACTIVE PHARMACEUTICAL INGREDI-
8
ENTS.— 
9
‘‘(i) IN GENERAL.—The Office shall 
10
manufacture, or enter into contracts with 
11
entities to manufacture, an active pharma-
12
ceutical ingredient applicable to a drug or 
13
biological product that is either an applica-
14
ble COVID–19 product or an applicable 
15
drug or biological product if— 
16
‘‘(I) the Office determines that 
17
such ingredient is not readily available 
18
from existing suppliers or the existing 
19
supply of such ingredient to the do-
20
mestic market is vulnerable to disrup-
21
tion; 
22
‘‘(II) the manufacture of such in-
23
gredient would improve the ability of 
24
other entities to enter the market for 
25
22:57 Feb 21, 2021
H728
13 
•HR 728 IH
the 
manufacture 
of 
applicable 
1
COVID–19 products or applicable 
2
drugs, biological products, or devices, 
3
or otherwise expand the manufacture 
4
of applicable COVID–19 products or 
5
applicable drugs, biological products, 
6
or devices; or 
7
‘‘(III) the manufacture of such 
8
ingredient is necessary for the Office 
9
to carry out its duties under this sec-
10
tion. 
11
‘‘(ii) 
PRICE
DETERMINATIONS.—In 
12
determining the price at which to sell an 
13
active pharmaceutical ingredient manufac-
14
tured in accordance with clause (i), the Of-
15
fice shall consider the cost to manufacture 
16
the ingredient, the administrative costs of 
17
the Office with respect to the ingredient, 
18
and the impact of such price on market 
19
competition for the ingredient. 
20
‘‘(E) PRIORITY.—In awarding contracts 
21
under this paragraph, the Office shall prioritize 
22
entities manufacturing applicable COVID–19 
23
products and applicable drugs, biological prod-
24
22:57 Feb 21, 2021
H728
14 
•HR 728 IH
ucts, and devices using components originating 
1
and manufactured in the United States. 
2
‘‘(F) CONTRACT REQUIREMENTS.—All con-
3
tracts issued under this paragraph shall include 
4
a requirement that the contract recipients rea-
5
sonably price products produced under the con-
6
tract. 
7
‘‘(b) MANUFACTURING OF PRODUCTS.— 
8
‘‘(1) IN
GENERAL.—As soon as practicable 
9
after the date of enactment of this section, but no 
10
later than 1 month after such date of enactment, the 
11
Office shall begin— 
12
‘‘(A) manufacturing, or entering into con-
13
tracts with entities for the manufacture of ap-
14
plicable COVID–19 products and applicable 
15
drugs, 
biological 
products, 
and 
devices, 
16
prioritizing drugs, biological products, devices 
17
or personal protective equipment the manufac-
18
ture of which would provide the greatest public 
19
health impact; and 
20
‘‘(B) constructing, or entering into con-
21
tracts to construct, manufacturing facilities, in-
22
cluding the construction of advanced manufac-
23
turing technology, RNA vaccines, DNA vac-
24
cines, recombinant protein vaccines, viral vec-
25
22:57 Feb 21, 2021
H728
15 
•HR 728 IH
tor-based vaccines, live attenuated vaccines, in-
1
activated vaccines, or other therapeutics, after 
2
clinical data relating to such products have 
3
demonstrated strong positive indications of 
4
safety and efficacy, to ensure immediate pro-
5
duction at-scale upon Federal approval. 
6
‘‘(2) SUBMISSION OF APPLICATIONS.—For each 
7
applicable COVID–19 product, and for each applica-
8
ble drug, biological product, or device that the Office 
9
determines should be manufactured, as provided for 
10
under this section, the Secretary shall— 
11
‘‘(A) submit an application under sub-
12
section (b) or (j) of section 505, or under sec-
13
tion 515, of the Federal Food, Drug, and Cos-
14
metic Act or subsection (a) or (k) of section 
15
351 of this Act or submit a notification under 
16
section 510(k) of the Federal Food, Drug, and 
17
Cosmetic Act (or enter into a contract with an-
18
other entity to submit such an application or 
19
notification); 
20
‘‘(B) request an emergency use authoriza-
21
tion of the product under section 564A of the 
22
Federal Food, Drug, and Cosmetic Act (or 
23
enter into a contract with another entity to sub-
24
mit an application for such use); or 
25
22:57 Feb 21, 2021
H728
16 
•HR 728 IH
‘‘(C) obtain from the holder of an applica-
1
tion approved under subsection (c) or (j) of sec-
2
tion 505 or section 515 of the Federal Food, 
3
Drug, and Cosmetic Act or subsection (a) or 
4
(k) of section 351 of the Public Health Service 
5
Act, or cleared under section 510(k) of the Fed-
6
eral Food, Drug, and Cosmetic Act, rights to 
7
manufacture such applicable drug. 
8
‘‘(3) MANUFACTURING TIMELINES.— 
9
‘‘(A) 
PERSONAL
PROTECTIVE
EQUIP-
10
MENT.—Not later than 1 month after the date 
11
of enactment of this section, the Secretary shall 
12
begin the public manufacturing of personal pro-
13
tective equipment, including surgical masks, 
14
surgical gowns, face shields, and N95 masks, 
15
meeting the definition of applicable COVID–19 
16
product and in accordance with this section. 
17
‘‘(B) COVID–19 DIAGNOSTIC TEST MATE-
18
RIALS.—Not later than 1 month after the date 
19
of enactment of this section, the Secretary shall 
20
begin the public manufacturing of materials 
21
necessary for the development of COVID–19 di-
22
agnostic tests, including chemical reagents, test 
23
swabs, and materials necessary to develop sero-
24
logical COVID–19 tests, meeting the definition 
25
22:57 Feb 21, 2021
H728
17 
•HR 728 IH
of applicable COVID–19 product and in accord-
1
ance with this section. 
2
‘‘(C) COVID–19 TREATMENT DRUGS.—As 
3
soon as practicable after the date of enactment 
4
of this section, the Secretary shall begin the 
5
public manufacturing of drugs and biological 
6
products in shortage, and any devices used to 
7
administer such drugs and biological products, 
8
that are used for treatment of severe COVID– 
9
19 cases, including albuterol, drugs used to 
10
intubate patients, antibiotics, and antivirals, 
11
meeting the definition of applicable COVID–19 
12
product and in accordance with this section. 
13
‘‘(4) PRIORITY
MANUFACTURING.—The Office 
14
shall prioritize the manufacturing of applicable 
15
COVID–19 products and applicable drugs, biological 
16
products, and devices that would have the greatest 
17
impact on— 
18
‘‘(A) diagnosing, mitigating, preventing, 
19
treating, or curing COVID–19; 
20
‘‘(B) limiting the harm the COVID–19 
21
pandemic might otherwise cause to public 
22
health and the economy; 
23
‘‘(C) addressing shortages of drugs, bio-
24
logical, products, and devices; 
25
22:57 Feb 21, 2021
H728
18 
•HR 728 IH
‘‘(D) reducing the cost of combating 
1
COVID–19 to Federal, State, local, and Native 
2
health programs; and 
3
‘‘(E) alleviating demographic disparities in 
4
COVID–19 outcomes or access to diagnosis, 
5
mitigation, prevention, and treatment. 
6
‘‘(c) PROVISION OF PRODUCTS.— 
7
‘‘(1) PROVISION
OF
APPLICABLE
COVID–19 
8
PRODUCTS.—The Secretary shall provide applicable 
9
COVID–19 products at no cost to Federal, State, 
10
local, and Native health programs, and other domes-
11
tic health care providers and suppliers, including do-
12
mestic commercial health care providers, as deter-
13
mined by the Secretary, and sell at cost applicable 
14
COVID–19 products to other commercial entities 
15
and international entities. Amounts received from 
16
the sale of such drugs shall be used for the activities 
17
of the Office. 
18
‘‘(2) PROVISION OF APPLICABLE DRUGS, BIO-
19
LOGICAL PRODUCTS AND DEVICES.—The Secretary 
20
shall sell applicable drugs, biological products, and 
21
devices produced under this section at a fair price to 
22
other entities. Amounts received from the sale of 
23
such drugs shall be used to replenish the national 
24
strategic stockpile under section 319F–2. 
25
22:57 Feb 21, 2021
H728
19 
•HR 728 IH
‘‘(d) OVERSIGHT OF CONTRACTS.—In the case of ap-
1
plicable COVID–19 products and applicable drugs, bio-
2
logical products, and devices manufactured via contracts, 
3
the Inspector General of the Department of Health and 
4
Human Services shall conduct a review of not fewer than 
5
1 of every 3 contracts entered into under this section, and 
6
of the entities entering into such contracts, to ensure that 
7
the Office is issuing contracts under fair and reasonable 
8
terms and conditions, including facilitating the procure-
9
ment by the Federal Government of applicable COVID– 
10
19 products and applicable drugs, biological products, and 
11
medical devices at fair and reasonable prices. The Inspec-
12
tor General shall make each such review public and, in 
13
cases where such a review identifies unreasonable prices, 
14
submit recommendations to Congress on how the Office 
15
should improve its contracting systems to ensure reason-
16
able pricing. 
17
‘‘(e) REPORTS TO CONGRESS.—The Director shall 
18
prepare and submit to the President, the Committee on 
19
Health, Education, Labor, and Pensions of the Senate, 
20
and the Committee on Energy and Commerce of the 
21
House of Representatives, a monthly report during the 
22
public health emergency declared by the Secretary under 
23
section 319 on January 31, 2020, with respect to COVID– 
24
22:57 Feb 21, 2021
H728
20 
•HR 728 IH
19, and a final report 3 months after the public health 
1
emergency has concluded, that includes— 
2
‘‘(1) an assessment of the major supply chain 
3
challenges facing hospitals, medical providers, the 
4
Federal Government, State, local, and tribal govern-
5
ments, and the private sector in procuring drugs, bi-
6
ological products, devices, and personal protective 
7
equipment to combat and prevent the spread of 
8
COVID–19; and 
9
‘‘(2) a description of the status of all drugs, bi-
10
ological products, devices, active pharmaceutical in-
11
gredients, and personal protective equipment for 
12
which manufacturing has been authorized under this 
13
section, including drugs, biological products, devices, 
14
active pharmaceutical ingredients, and personal pro-
15
tective equipment being manufactured, drugs, bio-
16
logical products, devices, active pharmaceutical in-
17
gredients, and personal protective equipment for 
18
which the Office has submitted an application for 
19
approval or a notification for clearance or classifica-
20
tion to the Food and Drug Administration but has 
21
not yet received approval, clearance, or classification, 
22
and drugs, biological products, devices, active phar-
23
maceutical ingredients, and personal protective 
24
equipment for which the Office has received ap-
25
22:57 Feb 21, 2021
H728
21 
•HR 728 IH
proval, clearance, or classification from the Food 
1
and Drug Administration but are not being manu-
2
factured. 
3
‘‘(f) DEFINITIONS.—In this section: 
4
‘‘(1) APPLICABLE DRUG, BIOLOGICAL PRODUCT, 
5
OR DEVICE DEFINITION.—The term ‘applicable drug, 
6
biological product, or device’ means a drug (as de-
7
fined in section 201(g) of the Federal Food, Drug, 
8
and Cosmetic Act), biological product (as defined in 
9
section 351(i) of the Public Health Service Act), 
10
combination product (as described in section 503(g) 
11
of the Federal Food, Drug, and Cosmetic Act), or 
12
device (as defined in section 201(h) of the Federal 
13
Food Drug and Cosmetic Act) for which an ap-
14
proved application under section 505 or 515 of the 
15
Federal Food, Drug, and Cosmetic Act or section 
16
351 of the Public Health Service Act, or clearance 
17
under section 510(k) of the Federal Food, Drug, 
18
and Cosmetic Act, is in effect, and— 
19
‘‘(A) is included in the drug shortage list 
20
under section 506E of the Federal Food, Drug, 
21
and Cosmetic Act; or 
22
‘‘(B) is vulnerable to shortage. 
23
‘‘(2) APPLICABLE COVID–19 PRODUCT DEFINI-
24
TION.— 
25
22:57 Feb 21, 2021
H728
22 
•HR 728 IH
‘‘(A) IN GENERAL.—The term ‘applicable 
1
COVID–19 product’ means a product that is 
2
included on a list that the Secretary of Health 
3
and Human Services, in consultation with the 
4
Commissioner of Food and Drugs, the Assist-
5
ant Secretary for Preparedness and Response, 
6
and the Director of the Centers for Disease 
7
Control and Prevention, shall compile not later 
8
than 2 weeks after the date of enactment of 
9
this section and shall review and update, as 
10
necessary, every 2 weeks of— 
11
‘‘(i) qualified pandemic or epidemic 
12
products, as defined under section 319F– 
13
3, that are— 
14
‘‘(I)(aa) drugs, biological prod-
15
ucts, and devices that are manufac-
16
tured, 
used, 
designed, 
developed, 
17
modified, licensed or procured— 
18
‘‘(AA) to diagnose, mitigate, 
19
prevent, treat, or cure COVID– 
20
19; or 
21
‘‘(BB) to limit the harm the 
22
COVID–19 pandemic might oth-
23
erwise cause; 
24
22:57 Feb 21, 2021
H728
23 
•HR 728 IH
‘‘(bb) drugs, biological products, 
1
and devices that are manufactured, 
2
used, designed, developed, modified, li-
3
censed, or procured to diagnose, miti-
4
gate, prevent, treat, or cure a serious 
5
or life-threatening disease or condition 
6
caused by a product described in item 
7
(aa); or 
8
‘‘(cc) drugs, biological products, 
9
devices or technologies intended to en-
10
hance the use or effect of a drug, bio-
11
logical product, or device described in 
12
item (aa) or (bb); and 
13
‘‘(ii) personal protective equipment, 
14
including protective equipment for eyes, 
15
face, head, and extremities, protective 
16
clothing, respiratory devices, and protective 
17
shields and barriers, used to protect people 
18
from COVID–19 infection. 
19
‘‘(B) CONSULTATION.—In developing the 
20
list described in subparagraph (A), the Sec-
21
retary shall consult with the Administrator of 
22
the Federal Emergency Management Adminis-
23
tration and the Secretary of Defense to ensure 
24
that, in instances where the President has en-
25
22:57 Feb 21, 2021
H728
24 
•HR 728 IH
acted the Defense Production Act to produce 
1
applicable COVID–19 products, the Office does 
2
not replicate or overproduce products being de-
3
veloped under the Act. 
4
‘‘(3) NATIVE
HEALTH
PROGRAM.—The term 
5
‘Native health program’ shall include— 
6
‘‘(A) a program provided through the In-
7
dian Health Service; 
8
‘‘(B) any health program operated by— 
9
‘‘(i) an Indian tribe, or Tribal organi-
10
zation, as such terms are defined in section 
11
4 of the Indian Self-Determination and 
12
Education Assistance Act; 
13
‘‘(ii) an inter-tribal consortium, as de-
14
fined in section 501(a) of the Indian Self- 
15
Determination and Education Assistance 
16
Act; or 
17
‘‘(iii) an urban Indian organization, as 
18
defined in section 4 of the Indian Health 
19
Care Improvement Act; and 
20
‘‘(C) any health program provided through 
21
a Native Hawaiian health care system, as de-
22
fined in section 12 of the Native Hawaiian 
23
Health Care Improvement Act. 
24
22:57 Feb 21, 2021
H728
25 
•HR 728 IH
‘‘(4) DOMESTIC HEALTH CARE PROVIDER.—The 
1
term ‘domestic health care provider’ shall include the 
2
direct support professional, home health, and per-
3
sonal care attendant workforce. 
4
‘‘(g) AUTHORIZATION OF APPROPRIATIONS.—There 
5
are authorized to be appropriated such sums as may be 
6
necessary to carry out this section.’’. 
7
Æ 
22:57 Feb 21, 2021
H728
